Letter to Congress re: Regulatory pathway for hemp-derived cannabidiol (CBD)
Response to Congressional request for comment
The Center for Science in the Public Interest submits this comment in response to the July 2023
Congressional Request for Information regarding the potential for a regulatory pathway for
hemp-derived cannabidiol (CBD) products.
Tags
Topics